U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NYSE: TAK) | Delayed: 20.87 -0.04 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.91 | 52 Week High | $0.55 | |||
| Open | $20.88 | 52 Week Low | $0.55 | |||
| Day High | $21.17 | P/E | N/A | |||
| Day Low | $20.78 | EPS | $-0.20 | |||
| Volume | 2,650,795 | |||||
